AbbVie combination shows high SVR rates in genotype 1 hepatitis C which resisted direct-acting antivirals

15 April 2016

A trial by US drug major AbbVie (NYSE: ABBV) revealed 91% of genotype 1 (GT1) chronic hepatitis C virus (HCV) patients who failed previous therapy with direct-acting antivirals (DAAs), achieved sustained virologic response when treated with ABT-493 and ABT-530 with ribavirin (RBV).

This sustained virologic response at 12 weeks post-treatment (SVR12) was achieved after 12 weeks treatment with the combination.

Additionally, 86% of GT1 patients who received ABT-493 and ABT-530 without RBV, achieved SVR12.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK